US Bancorp DE Has $835,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

US Bancorp DE grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 77.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 163,106 shares of the company’s stock after purchasing an additional 71,065 shares during the quarter. US Bancorp DE owned about 0.11% of Adaptive Biotechnologies worth $835,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptive Biotechnologies during the third quarter worth $26,000. Rothschild Investment LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter worth $36,000. MQS Management LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter worth $36,000. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Adaptive Biotechnologies during the first quarter worth $46,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock worth $48,000 after acquiring an additional 11,852 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. BTIG Research upped their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average target price of $6.25.

Adaptive Biotechnologies Trading Up 3.4 %

NASDAQ ADPT opened at $5.82 on Friday. The stock has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $4.15. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $6.33.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Adaptive Biotechnologies had a negative return on equity of 60.99% and a negative net margin of 126.49%. The company had revenue of $46.44 million during the quarter, compared to the consensus estimate of $40.59 million. As a group, equities analysts predict that Adaptive Biotechnologies Co. will post -1.19 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.